GTPase, IMAP family member 7Genealiases: IAN7 · hIAN7
Q-omics provides the consensus-scored GIMAP7 profile across patient tissues and cancer cell-line models. GIMAP7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GIMAP7 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, GIMAP7 protein abundance shows 25,397 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, LUAD, and LSCC as cancer lineages where GIMAP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GIMAP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GIMAP7 survival associations across molecular data types. GIMAP7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GIMAP7 RNA expression–survival associations across cancer types. High GIMAP7 expression shows favorable associations in SKCM, HNSC, KIRC, CESC, LIHC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GIMAP7 RNA expression.
This table summarizes GIMAP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GIMAP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GIMAP7 shows lower tumor expression in LUAD, COAD, BLCA, THCA and KIRP and higher tumor expression in KIRC. The LUAD box plot shows higher GIMAP7 RNA expression in normal versus tumor tissue (log2 FC = −2.555, t-test p < 0.001).
This table shows molecular features associated with GIMAP7 in patient tissues and cancer cell lines. In patient samples, GIMAP7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GIMAP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
